Hicks Bethany, Jones Scott, Callaby Helen, Bailey Daniel, Gordon Claire, Rampling Tommy, Houlihan Catherine, Linley Ezra, Tonge Simon, Oeser Clarissa, Jones Rachael, Pond Marcus, Mehta Ravi, Wright Deborah, Hallis Bassam, Rowe Cathy, Otter Ashley
Emerging Pathogen Serology Group, Vaccine Development Evaluation and Preparedness Centre, UK Health Security Agency, Porton Down, Wiltshire, UK.
Emerging Pathogen Serology Group, Vaccine Development Evaluation and Preparedness Centre, UK Health Security Agency, Porton Down, Wiltshire, UK.
Vaccine. 2024 Dec 2;42(26):126453. doi: 10.1016/j.vaccine.2024.126453. Epub 2024 Oct 18.
The 2022 Monkeypox virus (MPXV) global outbreak boosted development of multiple serological assays to aid understanding of Mpox immunology.
The study aimed to assess a multiplexed solid-phase electrochemiluminescence immunoassay (Meso Scale Discovery (MSD)) for simultaneous detection of antibodies against MPXV, including A35, E8 and M1 antigens, along with corresponding Vaccina Virus (VACV) homologues and demonstrate its accuracy in assessing antibody titres post-vaccination and infection.
Assay performance was assessed for simultaneous detection of antibodies against MPXV and corresponding VACV antigens. Sensitivity and specificity were evaluated with paediatric negatives (n = 215), pre- and post-IMVANEX vaccinated (n = 80), and MPXV (Clade IIb, n = 39) infected serum samples.
The assay demonstrated high specificity (75.68 % (CI: 69.01-81.29) - 95.98 % (CI:92.54-97.87)) and sensitivity (62.11 % (CI:52.06-71.21) - 98.59 % (CI:92.44 %-99.93 %)) depending on the Orthopoxvirus antigen. Preferential binding was observed between MPXV-infected individuals and MPXV antigens, while vaccinated individuals exhibited increased binding to VACV antigens. These results highlight differential binding patterns between antigen homologues in related viruses.
Overall, this assay demonstrates high sensitivities in detecting antibodies for multiple relevant MPXV and VACV antigens post-infection and post-vaccination, indicating its utility in understanding immune responses to Orthopoxviruses in current and future outbreaks and evaluating the immunogenicity of new-generation Mpox-specific vaccinations.
2022年猴痘病毒（MPXV）全球暴发推动了多种血清学检测方法的开发，以帮助了解猴痘免疫学。
本研究旨在评估一种多重固相电化学发光免疫分析法（Meso Scale Discovery（MSD）），用于同时检测抗MPXV抗体，包括A35、E8和M1抗原，以及相应的痘苗病毒（VACV）同源物，并证明其在评估疫苗接种和感染后抗体滴度方面的准确性。
评估该检测方法同时检测抗MPXV抗体和相应VACV抗原的性能。使用儿科阴性样本（n = 215）、IMVANEX疫苗接种前后的样本（n = 80）以及MPXV（分支IIb，n = 39）感染的血清样本评估敏感性和特异性。
根据正痘病毒抗原的不同，该检测方法显示出高特异性（75.68%（CI：69.01 - 81.29）- 95.98%（CI：92.54 - 97.87））和敏感性（62.11%（CI：52.06 - 71.21）- 98.59%（CI：92.44% - 99.93%））。在MPXV感染个体和MPXV抗原之间观察到优先结合，而接种疫苗的个体与VACV抗原的结合增加。这些结果突出了相关病毒中抗原同源物之间的差异结合模式。
总体而言，该检测方法在检测感染后和疫苗接种后针对多种相关MPXV和VACV抗原的抗体方面显示出高敏感性，表明其在理解当前和未来疫情中正痘病毒的免疫反应以及评估新一代猴痘特异性疫苗的免疫原性方面具有实用性。
